epiH Search


Epidemiol Health > Volume 44; 2022 > Article
Epidemiology and Health 2022;44: e2022061-0.
DOI: https://doi.org/10.4178/epih.e2022061    Published online Jul 22, 2022.
Predictors of COVID-19 booster vaccine hesitancy among fully vaccinated adults in Korea: a nationwide cross-sectional survey
Yunha Noh1  , Ju Hwan Kim1  , Dongwon Yoon1  , Young June Choe2  , Seung-Ah Choe3,4  , Jaehun Jung5  , Sang-Won Lee1,6  , Ju-Young Shin1,6,7 
1School of Pharmacy, Sungkyunkwan University, Suwon, Korea
2Department of Pediatrics, Korea University Anam Hospital, Seoul, Korea
3Department of Preventive Medicine, Korea University College of Medicine, Seoul, Korea
4Division of Life Sciences, Korea University, Seoul, Korea
5Department of Preventive Medicine, Gachon University College of Medicine, Incheon, Korea
6Department of Biohealth Regulatory Science, Sungkyunkwan University, Suwon, Korea
7Department of Clinical Research Design & Evaluation, Samsung Advanced Institute for Health Sciences & Technology (SAIHST), Sungkyunkwan University, Seoul, Korea
Correspondence  Sang-Won Lee ,Email: sangwlee@skku.edu
Ju-Young Shin ,Email: shin.jy@skku.edu
Received: Mar 30, 2022  Accepted after revision: Jul 22, 2022
This study explored predictors of coronavirus disease 2019 (COVID-19) booster hesitancy among fully vaccinated young adults and parental COVID-19 vaccine hesitancy for their children.
This cross-sectional study administered an online survey from December 2 to December 20, 2021. We enrolled participants aged 18-49 years, for whom ≥2 weeks had passed after their initial COVID-19 vaccination. We estimated odds ratios (ORs) with 95% confidence intervals (CIs) using multivariate logistic regression to evaluate factors associated with booster/vaccine hesitancy.
Among the 2,993 participants, 48.8% showed hesitancy (wait and see: 40.2%; definitely not: 8.7%). Booster hesitancy was more common among women (OR, 1.25; 95% CI, 1.05 to 1.50), younger people (OR, 1.44; 95% CI, 1.17 to 1.77), those with a lower education level (OR, 2.05; 95% CI, 1.10 to 3.82), those who received the mRNA-1273 vaccine type (OR, 2.01; 95% CI, 1.65 to 2.45), and those who experienced serious adverse events following previous COVID-19 vaccination (OR, 2.03; 95% CI, 1.47 to 2.80). The main reasons for booster hesitancy were concerns about safety (54.1%) and doubts about efficacy (29.8%). Among the 1,020 respondents with children aged <18 years, 65.8% were hesitant to vaccinate their children against COVID-19; hesitancy was associated with younger parental age, education level, the type of vaccine the parent received, and a history of COVID-19 infection.
Concerns about the efficacy and safety of COVID-19 vaccines were the major barrier to booster acceptance. The initial COVID-19 vaccine type (mRNA-1273), young age, gender (women), a low education level, and adverse events after the first COVID-19 vaccine were key predictors of booster hesitancy.
Keywords: Coronavirus, Vaccine hesitancy, Immunization, Public health


Browse all articles >

Editorial Office
Department of Preventive Medicine, Yonsei University College of Medicine
50-1 Yonsei-ro, Seodaemun-gu, Seoul 03722, Korea
TEL: +82-2-745-0662   FAX: +82-2-764-8328    E-mail: office.epih@gmail.com

Copyright © 2022 by Korean Society of Epidemiology.

Developed in M2PI

Close layer
prev next